295 related articles for article (PubMed ID: 22382618)
41. Preclinical Pharmacokinetics and Dosimetry Studies of
Marsh IR; Grudzinski J; Baiu DC; Besemer A; Hernandez R; Jeffery JJ; Weichert JP; Otto M; Bednarz BP
J Nucl Med; 2019 Oct; 60(10):1414-1420. PubMed ID: 30926646
[TBL] [Abstract][Full Text] [Related]
42. Dosimetry for fractionated (131)I-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results.
Buckley SE; Saran FH; Gaze MN; Chittenden S; Partridge M; Lancaster D; Pearson A; Flux GD
Cancer Biother Radiopharm; 2007 Feb; 22(1):105-12. PubMed ID: 17627418
[TBL] [Abstract][Full Text] [Related]
43. Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.
Barrett JA; Joyal JL; Hillier SM; Maresca KP; Femia FJ; Kronauge JF; Boyd M; Mairs RJ; Babich JW
Cancer Biother Radiopharm; 2010 Jun; 25(3):299-308. PubMed ID: 20578835
[TBL] [Abstract][Full Text] [Related]
44. HIGH-DOSE 131I-MIBG THERAPIES IN CHILDREN: FEASIBILITY, PATIENT DOSIMETRY AND RADIATION EXPOSURE TO WORKERS AND FAMILY CAREGIVERS.
Cougnenc O; Defachelles AS; Carpentier P; Lervat C; Clisant S; Oudoux A; Kolesnikov-Gauthier H
Radiat Prot Dosimetry; 2017 Apr; 173(4):395-404. PubMed ID: 26940442
[TBL] [Abstract][Full Text] [Related]
45. Cotransfecting norepinephrine transporter and vesicular monoamine transporter 2 genes for increased retention of metaiodobenzylguanidine labeled with iodine 131 in malignant hepatocarcinoma cells.
Zhao Y; Zhong X; Ou X; Cai H; Wu X; Huang R
Front Med; 2017 Mar; 11(1):120-128. PubMed ID: 28213878
[TBL] [Abstract][Full Text] [Related]
46. Comparison of [123I]MIBG and [131I]MIBG for imaging of neuroblastoma and other neural crest tumors.
Liu B; Zhuang H; Servaes S
Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):21-8. PubMed ID: 23474632
[TBL] [Abstract][Full Text] [Related]
47. Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG.
Vaidyanathan G; Affleck DJ; Zalutsky MR
J Nucl Med; 1995 Apr; 36(4):644-50. PubMed ID: 7699460
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and Safety of
Maric I; Weber M; Prochnow A; Schmitz J; Unger N; Schaarschmidt BM; Poeppel TD; Rischpler C; Bockisch A; Herrmann K; Jentzen W; Fendler WP
J Nucl Med; 2023 Jun; 64(6):885-891. PubMed ID: 36732054
[TBL] [Abstract][Full Text] [Related]
49. Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to
Batra V; Gikandi A; Pawel B; Martinez D; Granger MM; Marachelian A; Park JR; Maris JM; Vo KT; Matthay KK; DuBois SG
Pediatr Blood Cancer; 2024 Jan; 71(1):e30743. PubMed ID: 37885116
[TBL] [Abstract][Full Text] [Related]
50. CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (
Grand-Guillaume J; Mansi R; Gaonkar RH; Zanger S; Fani M; Eugster PJ; Beck Popovic M; Grouzmann E; Abid K
J Transl Med; 2023 Sep; 21(1):604. PubMed ID: 37679770
[TBL] [Abstract][Full Text] [Related]
51. [131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter.
McCluskey AG; Boyd M; Ross SC; Cosimo E; Clark AM; Angerson WJ; Gaze MN; Mairs RJ
Clin Cancer Res; 2005 Nov; 11(21):7929-37. PubMed ID: 16278418
[TBL] [Abstract][Full Text] [Related]
52. Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT/CT over planar image in patients with malignant pheochromocytoma/paraganglioma and neuroblastoma.
Fukuoka M; Taki J; Mochizuki T; Kinuya S
Clin Nucl Med; 2011 Jan; 36(1):1-7. PubMed ID: 21157198
[TBL] [Abstract][Full Text] [Related]
53. Feasibility Study of Single-Photon Emission Computed Tomography with Iodine-123 Labeled Metaiodobenzylguanidine for Preclinical Evaluation of Labetalol as a β-Adrenergic Receptor Blocker.
Choi Y; Lee ES; Woo SK; Lee KC; Chung HK; Kang JH
Mol Pharm; 2024 May; 21(5):2435-2440. PubMed ID: 38626389
[TBL] [Abstract][Full Text] [Related]
54. Whole-body PET/CT with 11C-meta-hydroxyephedrine in tumors of the sympathetic nervous system: feasibility study and comparison with 123I-MIBG SPECT/CT.
Franzius C; Hermann K; Weckesser M; Kopka K; Juergens KU; Vormoor J; Schober O
J Nucl Med; 2006 Oct; 47(10):1635-42. PubMed ID: 17015899
[TBL] [Abstract][Full Text] [Related]
55. Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study.
Piccardo A; Lopci E; Conte M; Garaventa A; Foppiani L; Altrinetti V; Nanni C; Bianchi P; Cistaro A; Sorrentino S; Cabria M; Pession A; Puntoni M; Villavecchia G; Fanti S
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):57-71. PubMed ID: 21932116
[TBL] [Abstract][Full Text] [Related]
56. [(131)I] and [(125)I] metaiodobenzylguanidine therapy in macroscopic and microscopic tumors: a comparative study in SK-N-SH human neuroblastoma and PC12 rat pheochromocytoma xenografts.
Rutgers M; Buitenhuis CK; van der Valk MA; Hoefnagel CA; Voûte PA; Smets LA
Int J Cancer; 2000 Dec; 90(6):312-25. PubMed ID: 11180134
[TBL] [Abstract][Full Text] [Related]
57. Total-body scintigraphy with 131I-meta-iodobenzylguanidine for detection of neuroblastoma.
Hoefnagel CA; Voûte PA; de Kraker J; Marcuse HR
Diagn Imaging Clin Med; 1985; 54(1):21-7. PubMed ID: 3918823
[TBL] [Abstract][Full Text] [Related]
58. Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).
Trieu M; DuBois SG; Pon E; Nardo L; Hawkins RA; Marachelian A; Twist CJ; Park JR; Matthay KK
Pediatr Blood Cancer; 2016 Mar; 63(3):436-42. PubMed ID: 26506090
[TBL] [Abstract][Full Text] [Related]
59. Radiation quality-dependent bystander effects elicited by targeted radionuclides.
Boyd M; Sorensen A; McCluskey AG; Mairs RJ
J Pharm Pharmacol; 2008 Aug; 60(8):951-8. PubMed ID: 18644188
[TBL] [Abstract][Full Text] [Related]
60. Improved selectivity of mIBG uptake into neuroblastoma cells in vitro and in vivo by inhibition of organic cation transporter 3 uptake using clinically approved corticosteroids.
Bayer M; Schmitt J; Dittmann H; Handgretinger R; Bruchelt G; Sauter AW
Nucl Med Biol; 2016 Sep; 43(9):543-551. PubMed ID: 27376201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
